JP2022145646A - 長時間作用型成長ホルモンポリペプチドを投与する方法 - Google Patents

長時間作用型成長ホルモンポリペプチドを投与する方法 Download PDF

Info

Publication number
JP2022145646A
JP2022145646A JP2022042639A JP2022042639A JP2022145646A JP 2022145646 A JP2022145646 A JP 2022145646A JP 2022042639 A JP2022042639 A JP 2022042639A JP 2022042639 A JP2022042639 A JP 2022042639A JP 2022145646 A JP2022145646 A JP 2022145646A
Authority
JP
Japan
Prior art keywords
subject
long
rhgh
dose level
week
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022042639A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022145646A5 (https=
Inventor
アレクサンドラ、パストラック
Pastrak Aleksandra
ホセ、フランシスコ、カラ
Francisco Cara Jose
ミカエル、ポール、ワンラッチ
Paul Wajnrajch Michael
スリニヴァス、ラオ、ヴァルーリ
Rao Valluri Srinivas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Opko Biologics Ltd
Pfizer Inc
Original Assignee
Opko Biologics Ltd
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Biologics Ltd, Pfizer Inc filed Critical Opko Biologics Ltd
Publication of JP2022145646A publication Critical patent/JP2022145646A/ja
Publication of JP2022145646A5 publication Critical patent/JP2022145646A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/575—Hormones
    • G01N2333/65—Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2022042639A 2021-03-19 2022-03-17 長時間作用型成長ホルモンポリペプチドを投与する方法 Pending JP2022145646A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163163504P 2021-03-19 2021-03-19
US63/163,504 2021-03-19
US202163272417P 2021-10-27 2021-10-27
US63/272,417 2021-10-27

Publications (2)

Publication Number Publication Date
JP2022145646A true JP2022145646A (ja) 2022-10-04
JP2022145646A5 JP2022145646A5 (https=) 2025-03-24

Family

ID=83320806

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022042639A Pending JP2022145646A (ja) 2021-03-19 2022-03-17 長時間作用型成長ホルモンポリペプチドを投与する方法

Country Status (10)

Country Link
US (1) US20240166710A1 (https=)
EP (1) EP4308151A4 (https=)
JP (1) JP2022145646A (https=)
KR (1) KR20230171936A (https=)
AU (1) AU2022238386A1 (https=)
BR (1) BR112023018980A2 (https=)
CA (1) CA3214273A1 (https=)
IL (1) IL305661A (https=)
MX (1) MX2023010997A (https=)
WO (1) WO2022197961A1 (https=)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508465A (ja) * 2014-12-10 2018-03-29 オプコ バイオロジクス リミテッド 長時間作用性ｃｔｐ修飾成長ホルモンポリペプチドを生成する方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020155990A1 (en) * 2001-04-20 2002-10-24 Renasci, Inc., D/B/A Renasci Anti-Aging Center Method of optimizing growth hormone replacement
WO2009102734A1 (en) * 2008-02-11 2009-08-20 Depomed Inc. Methods for treating vasomotor symptoms using gaba analogs in a gastric retentive dosage form
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
RU2746943C2 (ru) * 2013-10-21 2021-04-22 Опко Байолоджикс Лтд. Полипептиды длительного действия и способы их получения и введения
DK3220892T3 (da) * 2014-11-21 2021-11-08 Ascendis Pharma Endocrinology Div A/S Langtidsvirkende væksthormondoseringsformer
HRP20230405T8 (hr) * 2014-12-10 2023-09-29 Opko Biologics Ltd. Metode proizvodnje dugo djelujućih ctp-modificiranih polipeptida hormona rasta

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018508465A (ja) * 2014-12-10 2018-03-29 オプコ バイオロジクス リミテッド 長時間作用性ｃｔｐ修飾成長ホルモンポリペプチドを生成する方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISHER, D. M. ET AL.: "Pharmacokinetic and Pharmacodynamic Modeling of MOD-4023, a Long-Acting Human Growth Hormone, in Gro", HORMONE RESEARCH IN PAEDIATRICS, vol. 87, no. 5, JPN6026004547, 2017, pages 324 - 332, ISSN: 0005792521 *
STRASBURGER, C. J. ET AL.: "MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 176, no. 3, JPN6026004545, 2017, pages 283 - 294, ISSN: 0005792522 *
ZELINSKA, N. ET AL.: "Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study i", THE JOURNAL OF CLINICAL ENDOCRINOLOGY AND METABOLISM, vol. 102, no. 5, JPN6026004546, 2017, pages 1578 - 1587, ISSN: 0005792523 *

Also Published As

Publication number Publication date
CA3214273A1 (en) 2022-09-22
MX2023010997A (es) 2023-11-28
EP4308151A1 (en) 2024-01-24
WO2022197961A1 (en) 2022-09-22
BR112023018980A2 (pt) 2023-12-05
AU2022238386A1 (en) 2023-09-14
US20240166710A1 (en) 2024-05-23
IL305661A (en) 2023-11-01
EP4308151A4 (en) 2025-02-26
KR20230171936A (ko) 2023-12-21

Similar Documents

Publication Publication Date Title
US12029780B2 (en) Long-acting polypeptides and methods of producing and administering same
Gharib et al. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in adults and children—2003 update
Kopchick et al. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly
Reh et al. Somatotropin in the treatment of growth hormone deficiency and Turner syndrome in pediatric patients: a review
EA035352B1 (ru) Способ лечения дефицита соматотропного гормона
AU2022246472A1 (en) Long-acting polypeptides and methods of producing and administering same
US20140162954A1 (en) Fusion of human growth hormone and albumin formulation and uses thereof
Emerson et al. Recombinant human thyroid-stimulating hormone: pharmacology, clinical applications and potential uses
US20160271265A1 (en) Insulin-like growth factor mimetics for use in therapy
CN117425490A (zh) 施用长效生长激素多肽的方法
JP2022145646A (ja) 長時間作用型成長ホルモンポリペプチドを投与する方法
Bouhours-Nouet et al. Long-acting recombinant human growth hormone in the treatment of pediatric growth hormone deficiency, how far have we got?
HK40098775A (zh) 施用长效生长激素多肽的方法
Hasegawa et al. Current understanding and perspectives on growth and long-acting GH therapy in Japan
Dao et al. Human growth hormone
Class et al. Patent application title: FUSION OF HUMAN GROWTH HORMONE AND ALBUMIN FORMULATION AND USES THEREOF Inventors: Kurt Brown (Narbeth, PA, US) Merav Bassan (Netanya, IL) Assignees: Teva Pharmaceutical Industries Ltd.
Lee Growth hormone and Prader-Willi syndrome: experience and perspective
Dao et al. Human growth hormone
Steelman et al. Cara, CL Roland, CT Taylor, SR Valluri, and MP Wajnrajch are employees
Ying et al. Once-Weekly Lonapegsomatropin Was Efficacious and Well Tolerated in Chinese Children with Growth Hormone Deficiency: Results from a Phase 3 Randomized Trial
Luz et al. History and Current Status of Growth Hormone Treatment in Children: CC Luz, PF Collett-Solberg
Rogol et al. History of Growth Hormone: Animal to Human
Kochar Recent Trends in Use of Growth Hormone Therapy
HK40034109A (en) Long-acting polypeptides and methods of producing and administering same
Mason 16th International Congress of Endocrinology/96th Annual Meeting and Exposition of the Endocrine Society (ICE/ENDO), Chicago, Illinois, USA-June 21-24, 2014

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250313

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250313

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250314

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20251226

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260210